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Abstract
Background: Presentation of citrullinated neo-epitopes by HLA-DRB1 molecules that carry the shared epitope (SE)
sequence was proposed to explain the association between HLA and seropositive RA. Although it is shown that
several HLA-DRB1-SE molecules display enhanced binding affinities for citrullinated ligands, the ability of other HLA
molecules to present citrullinated epitopes has not been investigated in a systematic manner. To better understand
the HLA-RA connection, we aimed to investigate if the enhanced capacity to present arginine-to-citrulline-converted
peptides is unique for HLA-SE alleles.
Methods: We selected four HLA molecules (one HLA-DR and three HLA-DQ molecules) that could potentially prefer
citrulline over arginine residues in specific pockets and in addition two HLA-SE alleles as a method validation control.
The affinity of peptides containing arginine/citrulline residues at positions interacting with the various peptide-binding
pockets was compared by HLA class II peptide affinity assays.
Results: Pocket 4 of HLA-DRB1*04:04 and -DRB1*04:05 displayed a preference for citrulline over arginine, a property
found in other pockets as well. HLA-DRB1*03:01 did not display an enhanced affinity for peptides containing a
citrulline. In contrast, several peptide-binding pockets of the analyzed HLA-DQ molecules showed enhanced
affinities for citrulline compared to arginine residues: i.e., pockets 4, 6, 7, and 9 of HLA-DQ2 and pockets 1, 6,
and 9 of HLA-DQ7 and HLA-DQ8.
Conclusions: Arginine-to-citrulline conversion of peptides can also enhance the binding affinity for non-HLA-
SE molecules. Hence the capacity to present citrullinated neo-epitopes is not confined to HLA-SE molecules,
opening the possibility that also other HLA molecules could potentiate a possible breach of T cell tolerance
toward citrullinated antigens.
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Background
Rheumatoid arthritis (RA) patients can be divided in two
distinct subsets based on the presence of anti-citrullinated
protein antibodies (ACPA) [1, 2]. These autoantibodies
target proteins that have undergone posttranslational
modifications converting positively charged arginine to
uncharged citrulline residues [3].
The most important risk factor for ACPA-positive RA
is the human leukocyte antigen (HLA) class II locus [2].
This locus contains many genes, including genes encod-
ing the beta chain of HLA-DR (HLA-DRB1) and the
alpha and beta chain of HLA-DQ (HLA-DQA1 and
HLA-DQB1) that are inherited together in haplotypes. In
1987, it was proposed that the risk of developing ACPA-
positive RA is explained by the HLA-DRB1 locus, in par-
ticular by those alleles that carry the sequence QKRAA,
QRRAA or RRRAA in positions 70–74 of the DRB1 chain,
also known as the shared epitope (SE) motif [4, 5]. About
80 % of ACPA+ RA patients carry “HLA-SE” alleles, illus-
trating that these alleles are highly prevalent, but not re-
quired to develop seropositive disease [2].
The ligand-binding groove of HLA class II molecules
is composed of both the alpha and beta chains and is in-
volved in the presentation of peptides to CD4+ T cells.
The ligands accommodated by HLA class II molecules
vary in length, but the part that interacts most strongly
with this groove is 9 amino acids (AA) in length. The
amino acids within this part, also referred to as the peptide
core, are anchored within the groove in peptide-binding
pockets. These pockets accommodate the side chains of
peptide residues 1, 4, 6, 7, and 9 and are respectively
named: pocket 1, 4, 6, 7, and 9 [6].
The amino acid residues that shape the peptide-
binding pockets are highly polymorphic, thereby dictat-
ing the preferences for particular amino acids that can
be accommodated in the pockets of different HLA class
II alleles. In this way, the combined characteristics of the
peptide-binding pockets shape the repertoire of ligands
presented by the HLA molecule. The amino acids form-
ing the SE motif are part of pocket 4 of the HLA-DRB1
molecule [4, 6]. It was proposed that the SE motif asso-
ciates with risk because the positively charged SE resi-
dues would prevent the accommodation of positively
charged arginine residues while favoring the accommo-
dation of uncharged citrulline residues in pocket 4 [7].
The conversion of arginine to citrulline could thereby
result in the presentation of a peptide that would other-
wise not be present [7]. Indeed, several studies have shown
that pocket 4 of HLA-SE alleles HLA-DRB1*01:01,
*04:01, *04:04, and *10:01 prefers citrulline over arginine
residues [7–9].
It was postulated that this preference for citrulline
over arginine residues would be unique to HLA-SE al-
leles, but this was never analyzed [7]. We aimed to study
if non-HLA-SE alleles could also present citrullinated
peptides with enhanced affinity.
Methods
Cell lines
Lysates of Epstein-Barr virus (EBV)-transformed lympho-
blastoid B cell lines were used as a source for HLA-DQ/DR
molecules: BOLETH (DQA1*03:01/DQB1*03:02), BSM
(DQA1*03:01/DQB1*03:02), DUCAF (DRB1*03:01/
DQA1*05:01/DQB1*02:01), JSM (DQA1*03:02/
DQB1*03:01), and YOT (DRB1*04:05). Cells were
maintained in Iscove’s modified Dulbecco’s medium
(IMDM) (Lonza Bioresearch, Basel, Switzerland) supple-
mented with 8 % heat-inactivated fetal calf serum (FCS)
(Gibco; Life Technologies, Carlsbad, CA, USA), 1 %
penicillin, streptomycin, and GlutaMAX (Invitrogen,
Carlsbad, CA, USA).
Peptides
Peptides were synthesized according to standard Fmoc
(N-(9-fluorenyl)methoxycarbonyl) chemistry using a Syr-
oII peptide synthesizer (MultiSynTech, Witten, Germany).
The integrity of the peptides was verified using reverse-
phase high-performance liquid chromatography (HPLC)
and mass spectrometry (MS). For binding studies on
HLA-DR4 molecules we used macrophage migration
inhibition factor (MIF)33-47 KPPQYIAVHVVPDQL and
apolipoprotein B-100 (ApoB)2588-2603 PDFIVPLTDL
RIPSVQ, for HLA-DR3 myoglobin peptide138-148 LFRKD
IAAKYK, for HLA-DQ2 major histocompatibility com-
plex (MHC) class I alpha50-62 PWIEQEGPEFWDQ, and
for HLA-DQ7 and HLA-DQ8 herpes simplex virus (HSV)
2 peptide VP16432-444 VDMTPADALDDFD. The anchors
are depicted in bold. These peptides were previously
described in the context of the studied HLA molecules
[10–12]. To assess arginine or citrulline accommodation,
peptides with an arginine or a citrulline at the indicated
anchor positions were generated. As negative control pep-
tides, we used the following peptides that do not bind to
the respective HLA molecules: for HLA-DR4 and -DR3
we used AAAAKAAAAA, for HLA-DQ2 AKPFPQPEA-
PYKA, and for HLA-DQ7.3 and HLA-DQ8 AADTN
RWSKMDAA (data not shown).
HLA class II competitive peptide-binding assay
Peptide-binding assays were performed, as previously
described [13]. In short, cell lysates from HLA class II
homozygous B-lymphoblastoid cell lines were incubated
on SPV-L3- (anti-HLA-DQ)- or B8.11.2- (anti-HLA-DR)-
coated (10 μg/ml) FluoroNunc 96-well plates at 4 °C
overnight. Test peptides in the range of 0 to 300 μM were
mixed with a fixed concentration (0.6 μM) of biotinylated
indicator peptide and added to the wells. Bound indicator
peptide was detected using Europium-streptavidin
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(PerkinElmer, Boston, MA, USA) and measured in a time-
resolved fluorometer (PerkinElmer, Wallac Victor2). IC50
values were calculated based upon the observed binding
of the test peptide against the fixed concentration indica-
tor peptide. The IC50 value depicts the concentration of
test peptide required for a loss of 50 % of the indicator
peptide signal. IC50 values greater than 300 μM were
classified as non-detectable binding.
Statistical analysis
Wilcoxon’s signed-rank test was used to assess differences
in IC50 values between citrulline- and arginine-containing
peptides. P values below 0.05 were considered to be statis-
tically significant.
Model structures
Model structures of peptides citrullinated in specific
pockets were obtained by molecular simulation as previ-
ously described [13]. Essentially, the crystal structure
ls9v.pdb was used for modeling of HLA-DQ2 peptide
complexes. The Discover Suite (programs Insight II and
Discover) of Accelrys Software Inc. (San Diego, CA,
USA, release of 2005) was used on a Silicon Graphics
Fuel (Mountain View, CA, USA) instrument, using a
standard minimization approach. Occasionally, runs were
performed on a Silicon Graphics Octane instrument with
previous releases of the same software obtaining very simi-
lar results. Minimizations were carried out at pH 5.4 (endo-
somal pH), the same pH used in the peptide-binding
assays. Figures are drawn using the WebLabViewer
v3.5 and DSViewerPro software of Accelrys, the latter
currently freely available on the web. The coordinates
of the minimized structures are available to interested
researchers upon request to Dr. G. K. Papadopoulos
(gpapadop@teiep.gr).
Results
Presentation of arginine and citrulline residues by HLA-DR3
The genes encoding for HLA-DRB1, HLA-DQA1 and
HLA-DQB1 are highly polymorphic and many different
alleles have been identified in the human population.
The residues within the HLA molecules involved in
shaping peptide-binding pockets are known [6]. To se-
lect for HLA-DRB1 alleles that could potentially prefer
citrulline over arginine residues, we made use of a MHC
motif viewer [14], a web server that displays peptide-
binding motifs for all HLA-DR alleles using a predictive
algorithm. We searched for non-SE alleles that are com-
mon in Caucasians and that display a predicted prefer-
ence for negatively charged amino acids. In this way, we
selected HLA-DRB1*03:01 (abbreviated to HLA-DR3), one
of the most common HLA-DR molecules in Caucasians,
for further studies. HLA-DR3 was predicted to have a
strong preference for negatively charged amino acids in
pocket 4. As a control, the SE allele HLA-DRB1*04:04 and
HLA-DRB1*04:05 were taken along to validate the experi-
mental setup by comparing acquired data with published
data. Figure 1a depicts the amino acid residues of
HLA-DR3 and both HLA-DRB1*04 molecules involved
in shaping the various binding pockets. Of all three
HLA molecules, peptide-binding pocket 4 has a net
positive charge, thereby explaining the predicted prefer-
ence for negatively charged or neutral AA residues.
To systematically analyze if arginine-to-citrulline
conversions of peptides enhanced the affinity for HLA-
DRB1*04:04, HLA-DRB1*04:05, and HLA-DR3, we se-
lected an ApoB, MIF, and myoglobin peptide respectively
which were previously described to be accommodated
by these alleles and for which the peptide-binding register
is known [11, 15]. Next, we substituted each of the pep-
tide positions interacting with peptide-binding pockets
of the HLA molecule for arginine or citrulline residues.
The effect of these substitutions was subsequently stud-
ied in peptide-binding assays. In this way, a systematic
characterization of the ability of each of the peptide-
binding pockets to accommodate arginine or citrulline
residues was performed.
As depicted in Fig. 1b and c, HLA-DRB1*04:04 and
HLA-DRB1*04:05 have a strong preference for citrulline
over arginine in pocket 4, compatible with previously
published data. Furthermore, it is apparent that also
pockets 1, 6, and 9 of HLA-DRB1*04:05 prefer citrulline
while pocket 7 does not distinguish between the two
amino acids (Fig. 1c). On the other hand, as shown in
Fig. 1d, HLA-DR3 was unable to accommodate either
arginine or citrulline in pocket 4. Also for the other
peptide-binding pockets, arginine-to-citrulline conver-
sion did not result in enhanced peptide-binding affin-
ities, whereas in pocket 6 and 9, arginine residues were
preferred over citrulline.
Together, the data on the HLA-DRB1*04 molecules in-
dicate that the peptide-binding assays provide a valid
method to investigate amino acid preferences as pocket
4 prefers the accommodation of citrulline residues over
arginine residues. However, this feature does not only
apply to pocket 4, but also to other pockets accommo-
dating anchor residues from the antigenic peptide. In
contrast, the data indicate that HLA-DR3 does not have
a preference for citrulline in pocket 4 or any of the
pockets, while it prefers arginine residues as anchors in
pockets 6 and 9.
Presentation of arginine and citrulline residues by HLA-DQ
molecules
Genes encoding for HLA-DR and HLA-DQ molecules
are in tight linkage disequilibrium (LD) and inherit to-
gether in haplotypes. HLA-DQ molecules were recently
implicated in the pathogenesis of RA [13]. The ability of
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HLA-DQ molecules encoded by predisposing and non-
predisposing haplotypes to accommodate arginine and
citrulline residues has not been extensively studied, al-
though various peptides with varying anchor residues were
tested on different HLA II molecules to determine the
binding motif. Some HLA-DQ molecules were shown
to prefer negatively charged amino acid residues,
e.g., HLA-DQ2 (DQB1*02:01/DQA1*05:01), HLA-DQ7
(DQB1*03:01/DQA1*03:02), and HLA-DQ8 (DQB1*03:02/
DQA1*03:01), each in distinct pockets or combinations of
pockets. The latter two HLA molecules are particularly in-
teresting as these are encoded by genes that are in tight LD
with SE alleles and hence also associate with RA risk [13].
Figure 2a shows the amino acids shaping the various
peptide-binding pockets of these HLA-DQ molecules.
To systematically analyze whether arginine-to-citrulline
conversion of peptides enhanced their affinity for HLA-
DQ molecules, we used a similar approach as applied for
HLA-DR3. As the myoglobin peptide cannot be presented
by these HLA-DQ molecules, we used two previously de-
scribed ligands derived from MHC class I alpha antigen
(for HLA-DQ2) and from herpes simplex virus VP16-
protein (for HLA-DQ7 and HLA-DQ8) for which the
binding register has been established [10, 12]. By using
peptides that contained either an arginine or citrulline
residue at defined anchor positions, we were able to show
that all three HLA-DQ molecules preferred citrulline over
arginine residues in different peptide-binding pockets of
the HLA molecules. HLA-DQ7 (Fig. 2c) and HLA-DQ8
(Fig. 2d) preferred citrulline over arginine residues as an-
chors in peptide-binding pockets 1, 6, and 9, whereas
HLA-DQ2 (Fig. 2b) molecules preferred citrulline residues
in pockets 4, 6, 7, and 9, with a relatively high binding
affinity for the latter two pockets.
It is evident from the peptide-binding experiments
that the three HLA-DQ molecules tested are capable of
binding citrulline-containing peptides. Molecular simula-
tion was used in order to obtain a better appreciation of
Fig. 1 Accommodation of citrulline and arginine residues by HLA-DR4 and HLA-DR3 molecules. a Schematic representation of the peptide-binding
pockets of HLA-DR4 and HLA-DR3. Amino acid (AA) residues are color coded according to their properties (white = hydrophilic, gray= hydrophobic,
red = acidic, blue= basic). b Competitive binding of a biotin-labeled ApoB peptide with an unlabeled ApoB peptide or ApoB variants with arginine or
citrulline residues in p1, p4, p6, p7, and p9 to HLA-DRB1*04:04. c Competitive binding of a biotin-labeled MIF peptide with an unlabeled MIF peptide
or MIF variants with arginine or citrulline residues in p1, p4, p6, p7, and p9 to HLA-DRB1*04:05. d Competitive binding of a biotin-labeled myoglobin
peptide with an unlabeled myoglobin peptide or myoglobin variants with arginine or citrulline residues in p1, p4, p6, p7, and p9 to HLA-DR3. Graphs
depict the IC50 values (μM). ND non-detectable binding. Binding experiments were performed at least three times and plots show pooled experiments.
The error bars show the standard error of the mean. *Indicates a p value of <0.05
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the molecular interactions facilitating the enhanced
binding of citrulline-containing peptide used in the bind-
ing assays, in the context of HLA-DQ2. As is depicted
in Fig. 3 and in line with the peptide-binding data, cit-
rulline residues are predicted to be accommodated by
both peptide-binding pocket 7 and 9 without any con-
straints in the surrounding residues or the anchor itself
(Fig. 3a–b). Likewise, the model structure of arginine in
pocket 9 predicts the accommodation of arginine within
the pocket with only small rearrangements of the sur-
rounding residues (Fig. 3c). The difference in binding
affinity shown by the peptide-binding experiments is
likely to be caused by the repulsion of the p9 arginine
residue by the α76Arg in pocket 9.
Together these data demonstrate that an arginine-to-
citrulline conversion can also enhance the peptide-binding
affinity of peptides for several HLA-DQ molecules,
thereby indicating that this property is not confined to
HLA-DR-SE alleles. These data are important as they indi-
cate that also HLA-DQ molecules could contribute to the
induction of T cell immunity directed against citrullinated
peptides, a mechanism thought to contribute to the auto-
immune response underlying RA.
Discussion
Over a decade ago, it was first demonstrated that
arginine-to-citrulline conversion enhances the affinity of
peptides for HLA-DRB1-SE alleles [7, 8]. It was sug-
gested that this feature is unique to HLA-SE alleles and
could thereby explain the HLA-RA connection. We have
now analyzed HLA-SE and non-SE alleles and demon-
strate that in addition to the HLA-DR-SE alleles, several
HLA-DQ molecules also have the enhanced capacity to
present citrullinated peptides as we show that peptides
harboring a citrulline instead of an arginine in anchor
positions display an enhanced affinity. Moreover, we
Fig. 2 Accommodation of citrulline and arginine residues by HLA-DQ molecules. a Schematic representation of the differences in peptide-binding
pockets between HLA-DQ2, HLA-DQ7 and HLA-DQ8. Amino acid (AA) residues are color coded according to their properties (white = hydrophilic, gray
= hydrophobic, red = acidic, blue = basic). b Competitive binding of a biotin-labeled alpha-gliadin peptide with an unlabeled alpha-gliadin peptide or
alpha-gliadin variants with citrulline or arginine residues in p1, p4, p6, p7, and p9 to HLA-DQ2. c–d Competitive binding of a biotin-labeled VP16
peptide with an unlabeled VP16 peptide or VP16 variants with citrulline or arginine residues in p1, p4, p6, p7, and p9 to HLA-DQ7 (c) and
HLA-DQ8 (d). Graphs depict the IC50 values (μM). ND non-detectable binding. Binding experiments were performed at least three times and
plots show pooled experiments. The error bars show the standard error of the mean. *Indicates a p value of <0.05
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show that not only pocket 4, but also other pockets
within HLA-DRB*04 molecules show a preference for
citrulline over arginine.
Determining the capacity to present citrullinated neo-
epitopes for all different HLA molecules would require a
large-scale approach given the fact that hundreds of
different HLA-DR and HLA-DQ molecules have been
described. However, the amino acid positions important
for shaping peptide-binding pockets have been eluci-
dated, thereby allowing the prediction of HLA-DQ and
HLA-DR alleles that are likely to possess the ability to
present citrullinated neo-epitopes. In this study, we
focused on only a few SE-positive and SE-negative HLA
class II molecules, present in relatively high frequency in
the Caucasian population and that have not been studied
before in this regard, and which are likely able to present
citrullinated neo-epitopes. However, it is highly conceiv-
able that also other HLA-DR or HLA-DQ molecules
share similar capacities.
HLA-DRB1-SE alleles have been studied extensively
with regard to their ability to present citrullinated pep-
tides derived from antigens implicated in RA pathogen-
esis, for example peptides derived from vimentin and
enolase [8]. For the majority of the SE alleles, it has been
shown that these citrullinated peptides are accommo-
dated in a more efficient fashion than the native forms
[16, 17]. To the best of our knowledge, the capacity of
HLA-DQ molecules to present citrullinated ligands has
not yet been investigated. Interestingly, in a recent study,
it was shown that T cells from HLA-DQ8 transgenic
mice immunized with collagen type II (CII) respond bet-
ter to citrullinated CII than to native CII, which could
Fig. 3 Model structures of citrulline residue accommodation in peptide-binding pockets 7 and 9 of HLA-DQ2. a T cell receptor (TCR)-view of the
p7Cit anchor and the surrounding pocket 7 residues. The residues of pocket 7 are in van der Waals surface representation (partially transparent)
with surfaces colored according to atomic charges (negative, red; neutral, gray; positive, blue). In addition, the HLA-DQ2 residues are shown in stick
form (carbon, orange; oxygen, red; nitrogen, blue; hydrogen, white; sulfur, yellow). The p7 citrulline residue is depicted in space-filling form with
the same color code as the stick form residues, except for carbon, which is in green. The figure is tilted with respect to the proper TCR view by
+25 ° and +10 ° with respect to the x-axis and y-axis respectively. b TCR view of the p9Cit anchor and the surrounding pocket 9 residues. Colors
and conventions as in A. Figure is tilted with respect to the proper TCR view by +5 ° and -10 °C with respect to the x-axis and y-axis respectively.
c TCR view of the p9Arg anchor and the surrounding pocket 9 residues. Colors and conventions as in A. Figure is tilted as in B
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be explained by an enhanced capacity of HLA-DQ8 to
present citrullinated neo-epitopes [18], though the binding
was not shown in a direct approach. A limitation of our
study is that we cannot formally rule out the possibility
that our findings are influenced by the co-precipitation of
HLA-DRB4 and HLA-DRB3 molecules as these molecules
are co-expressed with HLA-DRB1*04 and HLA-DRB1*03
respectively. However, we anticipate that this influence,
if present, is minimal because the binding registers of
these HLA molecules differ substantially from the bind-
ing registers of HLA-DRB1*04 and HLA-DRB1*03.
Moreover, the cell surface expression of HLA-DRB4
and HLA-DRB3 is considerably lower as compared to
HLA-DRB1 molecules [19].
Conclusions
The hypothesis that predisposing HLA molecules associ-
ate with ACPA-positive RA because of their capacity to
present arginine-to-citrulline-converted epitopes with an
enhanced affinity may not completely explain the mo-
lecular basis for the association between HLA-DR1-SE
haplotypes and RA completely. It would, therefore, be
interesting to better comprehend the additional contri-
bution of the molecules encoded by the HLA-DRB1-SE
haplotypes to seropositive RA. Together, this study provides
a further refinement of the SE hypothesis and the possible
contribution of citrulline-containing T cell epitopes in the
pathogenesis of ACPA-positive RA via epitope presentation
by non-SE HLA-DQ alleles.
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